Louisa von Baumgarten1, Gerald Illerhaus, Agnieszka Korfel, Uwe Schlegel, Martina Deckert, Martin Dreyling. 1. Department of Neurology, Medical Center of the University of Munich (LMU), Munich; Department of Hematology, Oncology and Palliative Care, Stuttgart Cancer Center/Tumor Center Eva-Mayr-Stih, Klinikum Stuttgart; Medical Department, Division of Oncology and Hematology, Charité - Universitätsmedizin Berlin; Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum; Department of Neuropathology, University Hospital Cologne; Department of Internal Medicine III, Hospital of the University of Munich (LMU).
Abstract
BACKGROUND: Primary central nervous system lymphoma is a diffuse large B-celllymphoma with exclusive manifestation in the central nervous system (CNS), leptomeninges, and eyes. Its incidence is 0.5 per 100 000 persons per year.Currently, no evidence-based standard of care exists. METHODS: This review is based on pertinent publications (2000-2017) retrieved by aselective search in PubMed. RESULTS: The clinical and neuroradiological presentation of primary CNS lymphoma isoften nonspecific, and histopathological confirmation is obligatory. The disease, if left un- treated, leads to death within weeks or months. If the patient's general condition permits, treatment should consist of a high-dose chemotherapy based on methotrexate (HD- MTX) combined with rituximab and other cytostatic drugs that penetrate the blood-brain barrier. Long-term survival can be achieved in patients under age 70 by adding non- myeloablative consolidation chemotherapy or high-dose chemotherapy with autologous stem cell transplantation (HD-AST) to the induction therapy. Clinical trials comparing the efficacy and toxicity of these two treatment strategies are currently underway. Con- solidation whole-brain radiotherapy is associated with the risk of severe neurotoxicity and should be reserved for patients who do not qualify for systemic treatment. Some 30% of patients are refractory to primary treatment, and at least 50% relapse. In patients who are still in good general condition, relapse can be managed with HD-AST. Re- exposure to conventional HD-MTX-based polychemotherapy is another option, if the initial response was durable. The 5-year survival rate of all treated patients is 31%,according to registry data. CONCLUSION: Current recommendations for the treatment of primary CNS lymphomaare based on only a small number of prospective clinical trials. Patients with this disease should be treated by interdisciplinary teams in experienced centers, andpreferably as part of a controlled trial.
BACKGROUND:Primary central nervous system lymphoma is a diffuse large B-celllymphoma with exclusive manifestation in the central nervous system (CNS), leptomeninges, and eyes. Its incidence is 0.5 per 100 000 persons per year.Currently, no evidence-based standard of care exists. METHODS: This review is based on pertinent publications (2000-2017) retrieved by aselective search in PubMed. RESULTS: The clinical and neuroradiological presentation of primary CNS lymphoma isoften nonspecific, and histopathological confirmation is obligatory. The disease, if left un- treated, leads to death within weeks or months. If the patient's general condition permits, treatment should consist of a high-dose chemotherapy based on methotrexate (HD- MTX) combined with rituximab and other cytostatic drugs that penetrate the blood-brain barrier. Long-term survival can be achieved in patients under age 70 by adding non- myeloablative consolidation chemotherapy or high-dose chemotherapy with autologous stem cell transplantation (HD-AST) to the induction therapy. Clinical trials comparing the efficacy and toxicity of these two treatment strategies are currently underway. Con- solidation whole-brain radiotherapy is associated with the risk of severe neurotoxicity and should be reserved for patients who do not qualify for systemic treatment. Some 30% of patients are refractory to primary treatment, and at least 50% relapse. In patients who are still in good general condition, relapse can be managed with HD-AST. Re- exposure to conventional HD-MTX-based polychemotherapy is another option, if the initial response was durable. The 5-year survival rate of all treated patients is 31%,according to registry data. CONCLUSION: Current recommendations for the treatment of primary CNS lymphomaare based on only a small number of prospective clinical trials. Patients with this disease should be treated by interdisciplinary teams in experienced centers, andpreferably as part of a controlled trial.
Authors: Antonio Omuro; Denise D Correa; Lisa M DeAngelis; Craig H Moskowitz; Matthew J Matasar; Thomas J Kaley; Igor T Gavrilovic; Craig Nolan; Elena Pentsova; Christian C Grommes; Katherine S Panageas; Raymond E Baser; Geraldine Faivre; Lauren E Abrey; Craig S Sauter Journal: Blood Date: 2015-01-07 Impact factor: 22.113
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Joe S Mendez; Quinn T Ostrom; Haley Gittleman; Carol Kruchko; Lisa M DeAngelis; Jill S Barnholtz-Sloan; Christian Grommes Journal: Neuro Oncol Date: 2018-04-09 Impact factor: 12.300
Authors: B Kasenda; A J M Ferreri; E Marturano; D Forst; J Bromberg; H Ghesquieres; C Ferlay; J Y Blay; K Hoang-Xuan; E J Pulczynski; A Fosså; Y Okoshi; S Chiba; K Fritsch; A Omuro; B P O'Neill; O Bairey; S Schandelmaier; V Gloy; N Bhatnagar; S Haug; S Rahner; T T Batchelor; G Illerhaus; M Briel Journal: Ann Oncol Date: 2015-02-20 Impact factor: 32.976
Authors: Hendrik Pels; Annika Juergens; Axel Glasmacher; Holger Schulz; Andreas Engert; Michael Linnebank; Gabriele Schackert; Heinz Reichmann; Frank Kroschinsky; Marlies Vogt-Schaden; Gerlinde Egerer; Udo Bode; Carlo Schaller; Monika Lamprecht; Peter Hau; Martina Deckert; Rolf Fimmers; Christopher Bangard; Ingo G H Schmidt-Wolf; Uwe Schlegel Journal: J Neurooncol Date: 2008-10-18 Impact factor: 4.130
Authors: Anna Brunn; Inga Nagel; Manuel Montesinos-Rongen; Wolfram Klapper; Inga Vater; Werner Paulus; Volkmar Hans; Ingmar Blümcke; Joachim Weis; Reiner Siebert; Martina Deckert Journal: Acta Neuropathol Date: 2013-09-06 Impact factor: 17.088
Authors: James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan Journal: J Clin Oncol Date: 2013-04-08 Impact factor: 44.544
Authors: Gliceida M Galarza Fortuna; Kathrin Dvir; Christopher Febres-Aldana; Michael Schwartz; Ana Maria Medina Journal: J Investig Med High Impact Case Rep Date: 2019 Jan-Dec
Authors: Lian Duan; Jie Liu; Yan Zhang; Lijia Cui; Xiao Zhai; Boju Pan; Lin Lu; Hui Pan; Yong Yao; Huijuan Zhu Journal: Front Endocrinol (Lausanne) Date: 2021-02-04 Impact factor: 5.555